<DOC>
	<DOCNO>NCT00128700</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Vatalanib may stop growth tumor cell block blood flow tumor . Giving temozolomide radiation therapy together vatalanib may kill tumor cell . PURPOSE : This randomized phase I/II trial study side effect best dose vatalanib give together temozolomide radiation therapy see well work treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Temozolomide Radiation Therapy With Without Vatalanib Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended phase II dose vatalanib give combination temozolomide radiotherapy patient newly diagnose glioblastoma multiforme . ( Phase I ) - Determine safety tolerability regimen patient . ( Phase I ) - Determine 6-month progression-free survival patient treat chemoradiotherapy comprise temozolomide radiotherapy without vatalanib follow adjuvant therapy comprise temozolomide vatalanib temozolomide alone without maintenance therapy comprise vatalanib alone . ( Phase II ) Secondary - Determine 12-month overall survival patient treat regimen . ( Phase II ) - Determine toxicity profile regimens patient . ( Phase II ) - Correlate expression angiogenesis hypoxia marker MGMT methylation status clinical outcome patient treat regimen . OUTLINE : This phase I , multicenter , open-label , non-randomized , dose-escalation study vatalanib follow phase II , randomize , control study . Patients enrol phase II portion study stratify accord participate center , age ( &lt; 50 year vs ≥ 50 year ) , corticosteroid intake ( yes v ) , mini-mental status evaluation score ( &lt; 27 vs 27-29 v 30 ) . - Phase I : - Chemoradiotherapy : Patients receive oral temozolomide daily 6-7 week oral vatalanib daily 6 week . Patients also undergo radiotherapy daily , 5 day week , 6 week . Four week completion chemoradiotherapy , patient proceed adjuvant therapy . During 4-week period chemoradiotherapy adjuvant therapy , patient continue receive oral vatalanib twice daily . Cohorts 3-6 patient receive escalate dos vatalanib chemoradiotherapy maximum tolerate dose determine ( MTD ) . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . - Adjuvant therapy : Patients receive oral temozolomide daily day 1-5 oral vatalanib twice daily day 1-28 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients proceed maintenance therapy . - Maintenance therapy : Patients continue receive oral vatalanib twice daily absence disease progression unacceptable toxicity . - Phase II : Patients randomize 1 3 treatment arm . - Arm I : - Chemoradiotherapy : Patients receive oral temozolomide daily 6-7 week undergo radiotherapy daily , 5 day week , 6 week . Four week completion chemoradiotherapy , patient proceed adjuvant therapy . - Adjuvant therapy : Patients receive oral temozolomide daily day 1-5 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . - Arm II : - Chemoradiotherapy : Patients receive temozolomide undergo radiotherapy arm I . Patients also receive vatalanib twice daily 6 week MTD determine phase I . Four week completion chemoradiotherapy , patient proceed adjuvant therapy . During 4-week period chemoradiotherapy adjuvant therapy , patient continue receive oral vatalanib twice daily . - Adjuvant therapy : Patients receive temozolomide vatalanib phase I adjuvant therapy . Patients proceed maintenance therapy . - Maintenance therapy : Patients continue receive vatalanib phase I maintenance therapy . - Arm III : - Chemoradiotherapy : Patients receive temozolomide undergo radiotherapy arm I . Four week completion chemoradiotherapy , patient proceed adjuvant therapy . During 4-week period chemoradiotherapy adjuvant therapy , patient receive oral vatalanib twice daily . - Adjuvant therapy : Patients receive temozolomide vatalanib phase I adjuvant therapy . Patients proceed maintenance therapy . - Maintenance therapy : Patients continue receive vatalanib phase I maintenance therapy . After completion study treatment , patient follow every 3 month survival . PROJECTED ACCRUAL : Approximately 3-18 patient accrued phase I portion study . A total 201 patient ( 67 per treatment arm ) accrue phase II portion study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme Newly diagnose disease Deemed amenable concurrent adjuvant temozolomide treatment principal investigator PATIENT CHARACTERISTICS : Age 18 69 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin &lt; 1.5 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 2.5 time ULN ALT AST &lt; 2.5 time ULN Renal Creatinine ≤ 1.7 mg/dL Cardiovascular Cardiac function clinically normal 12lead ECG normal No ischemic heart disease within past 6 month No uncontrolled cardiac arrhythmia No uncontrolled hypertension No history stroke No history congenital long QT syndrome QTc interval ≤ 450 msec male ≤ 470 msec female 12lead ECG Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy except adequately treat basal cell squamous cell skin cancer cone biopsied carcinoma situ cervix No active uncontrolled infection No unstable systemic disease No psychological , familial , sociological , geographical condition would preclude study compliance followup schedule PRIOR CONCURRENT THERAPY : Biologic therapy No prior antivascular endothelial growth factor therapy Chemotherapy No prior chemotherapy Endocrine therapy Concurrent corticosteroid allow provided patient stable decreasing dos ≥ 2 week study entry Radiotherapy No prior radiotherapy Surgery More 8 day , &lt; 6 week , since prior surgery biopsy Other No prior randomization study No concurrent warfarin , warfarinderived drug , similar anticoagulant No concurrent anticancer therapy No concurrent investigational agent No concurrent enzyme induce antiepileptic drug , include follow : Carbamazepine Fosphenytoin Oxcarbazepine Phenobarbital Phenytoin Primidone No concurrent grapefruit grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>